Emergent BioSolutions history

The 2001 attacks created a huge new market as the government began filling the stockpile with treatments for anthrax and smallpox.

“Factoring in inflation and the increase in shelf-life, the price of BioThrax has actually dropped since the re-licensure of the facility and the DoD contract in 2002,” the company’s statement said.

Emergent spent nearly $4 million on lobbying last year alone — putting it in the upper echelon of all American companies despite its relatively small size — and about $43 million since it became publicly traded in 2006, according to data maintained by the Center for Responsive Politics.

Emergent became a publicly traded company in 2006, with its stock trading on the New York Stock Exchange under the symbol EBS.

“It is a very, very good business,” the vice president for investor relations, Robert G. Burrows, said in a 2010 presentation.

By 2010, the company had more than a quarter-billion dollars in annual revenue but only one product and one main customer: the United States government.

In response, the group of federal officials who make decisions about the stockpile and other emergency preparations — known as the Phemce, for the Public Health Emergency Medical Countermeasures Enterprise — ordered up a study. It found in 2010 that the government could not afford to devote so much of its budget to a single threat.

Bayview facility in Baltimore is acquired, later established in June 2012 as a Center for Innovation in Advanced Development and Manufacturing (CIADM) in a 25-year partnership with BARDA.

In June 2012, the government gave the company a contract to build an innovative laboratory in Baltimore — and left open the possibility of funding for future projects.

The last time anthrax appeared in the intelligence community’s annual Worldwide Threat Assessment, in 2012, the risk of a mass attack by a biological weapon was deemed “unlikely.” And Gregory F. Treverton, who directed the National Intelligence Council, which helped draft the assessments during Mr.

Emergent already has a ten-year contract with the Canadian military and national health service to supply BAT that began in 2012.

The company purchased Winnipeg, Manitoba's Cangene Corporation in 2013.

BAT was first licensed in the United States in 2013 and is the only botulism antitoxin available in the United States for naturally-occurring cases of non-infant botulism.

The spin-off was completed in August 2016 to form Aptevo Therapeutics.

In December 2016, Health Canada approved the purchase of Emergent's new botulism antitoxin called Botulism Antitoxin Heptavalent (BAT). The CDC and Public Health Agency of Canada both identified botulism, a type of food poisoning, as a likely biological threat.

At the time that order was announced, in 2016, the reserve already had enough to vaccinate more than 10 million people.

One business, American Medical Depot, pitched a reusable mask to the stockpile in 2016.

When Trump appointed him to lead ASPR in summer 2017, Kadlec was determined to shift the office’s efforts toward those goals.

The vaccine could reach stage-one clinical trials by early 2017.

An expansion of the Baltimore plant, finished in 2017, had $163 million in funding from the United States government.

In 2018, Emergent acquired Adapt Pharma, the manufacturer of Narcan (naloxone), a widely used nasal spray opioid-overdose antidote, for $735 million.

Emergent purchased (also in 2018) the specialty vaccine manufacturer PaxVax, whose product line includes FDA-approved typhoid vaccine Vivotif and cholera vaccine Vaxchora, from its owner, Cerebus Capital Management, a private equity fund.

J&J locked arms with Emergent in April 2020, enlisting the lesser-known company to manufacture the vaccine J&J was developing with federal money.

The FDA inspected Emergent’s Bayview plant in April 2020, just as the agreement with J&J was being announced.

In April 2020, the Department of Health and Human Services announced that it would not provide further funding for RiVax clinical trials, although the agency did not announce whether this was related to previous issues.

Emergent has invested heavily in lobbying the federal government, according to disclosure records that show the company spent $3.6 million on lobbying in 2020 alone.